doi: 10.1038/s41467-022-29124-8.
- PMID: 35379807
- DOI: 10.1038/s41467-022-29124-8
Abstract
Activation of the cannabinoid-1 receptor (CB1R) and the mammalian target of rapamycin complex 1 (mTORC1) in the renal proximal tubular cells (RPTCs) contributes to the development of diabetic kidney disease (DKD). However, the CB1R/mTORC1 signaling axis in the kidney has not been described yet. We show here that hyperglycemia-induced endocannabinoid/CB1R stimulation increased mTORC1 activity, enhancing the transcription of the facilitative glucose transporter 2 (GLUT2) and leading to the development of DKD in mice; this effect was ameliorated by specific RPTCs ablation of GLUT2. Conversely, CB1R maintained the normal activity of mTORC1 by preventing the cellular excess of amino acids during normoglycemia. Our findings highlight a novel molecular mechanism by which the activation of mTORC1 in RPTCs is tightly controlled by CB1R, either by enhancing the reabsorption of glucose and inducing kidney dysfunction in diabetes or by preventing amino acid uptake and maintaining normal kidney function in healthy conditions.
© 2022. The Author(s).
References
-
- Lovic, D. et al. The growing epidemic of diabetes mellitus. Curr. Vasc. Pharm. 18, 104–109 (2020).
-
- Gilbertson, D. T. et al. Projecting the number of patients with end-stage renal disease in the United States to the year 2015. J. Am. Soc. Nephrology: JASN 16, 3736–3741 (2005).
-
- Decleves, A. E. & Sharma, K. New pharmacological treatments for improving renal outcomes in diabetes. Nat. Rev. Nephrol. 6, 371–380 (2010). – PubMed
-
- Gilbert, R. E. Proximal tubulopathy: Prime mover and key therapeutic target in diabetic kidney disease. Diabetes 66, 791–800 (2017). – PubMed
